EFTA01017710.pdf

From: To: Cc: [email protected] Subject: Re: Date: Sat, 03 Nov 2018 18:31:41 +0000 Attachments: FHC overview 20 18.pdf; The_case_ for_ the _Female_Condorn 2018.pptx Hi Boris Currently The Female Health division of VERU supplies approximately 50 million Female Condoms worldwide. BMGF has never funded the FC2 Female condom. I don't know why this is the case. The FC2 female condom is the most demanded and utilized female condom worldwide. It is supplied throughout Africa via UNFPA and bought directly by South Africa. Funding by UNFPA has dramatically decreased and we are unable to supply certain countries that have requested the female condom. For example, the following countries have requested the FC2 female condom but we are unable to supply: Uganda : 3 million units Ghana: 1 million units Botswana: 1 million units Tunesia: 1 million units Sierra Leone: 500,000 units Bolivia: 500,000 units Tanzania: 1 million units Haiti: 500,000 units Ethiopia: 1 million units Congo DR: 2 million units Boris, can you introduce me to the right person at BMGF to see if we can get grants to provide FC2 female condoms to all women who request them in Africa. Also attached is more information regarding the FC2 female condom. Would like to continue the conversation. Sincerely, Harry ----Original Message From: Boris Nikolic To: harryfisch < Cc: jeevacation <[email protected]> Sent: Sat, Nov 3, 2018 1:27 pm EFTA01017710 Subject: RE: Re: Thank you Harry! Again — great meeting you. I am still laughing re inherited STD. Finally I had chance to read your slide deck. VERU is indeed very interesting company — congrats! You have an interesting mix of Urology specialty drugs (which I see as a low risk) and Prostate cancer drugs. Unfortunately my fund (https://www.biomaticscapital.comi) is only focused (and restricted to investing) on private companies. Mid-end of the next year I am going to fundraise a crossover fund which would allow me to invest in both private and publicly listed companies; nevertheless, I am now unable to invest in companies such as VERU — despite how interesting they might be. I looked at a female condom. I think that PATH supported a number of related projects. https://www.path.org/articles/seven-secrets-of-the-female-condom/ As you might know BMGF is the main donor to PATH — this is why I mentioned it. Also BMGF founded several smaller grants (GCE) re female condoms https://www.gatesfoundation.org/Media- Center/Press-Releases/2014/06/GCE-Round-12 In addition, there were grants to Imperial College in London, HealthRock etc. All of these are relatively old grants that ended. My guess is that all female condom more mature projects transitioned to PATH. Also I see that PSI has been funding marketing and delivery https://www.psi.org/2018/03/fresh-start-female-condom- marketing( Please let me know if there is anything else I can be of help to you. Hope to see you soon in NYC Best Boris From: Sent: Thursday, November 1, 2018 5:34 PM To: Boris Nikolic < [email protected] Subject: Re: Jeffrey thanks for introducing me to Boris. Boris, great meeting you as well. Attached is the most recent deck for VERU (NASDAQ: VERU) www.verupharma.com . In addition please look at We merged with The Female Health Company which sells the FC2 Female Condom to the public sector in Africa and Brazil via UNFPA and USAID. We just recently introduced this condom into the US market mainly via telemedicine. Would love to meet and discuss further. Sincerely, Harry Harry Fisch MD cell 914-552-2651 EFTA01017711 --Original Message-- From: Boris Nikolic To: J leevacationagmail.com>; Harry Fisch Sent Thu, Nov 1, 2018 4:13 pm Subject: RE: Thank you J! Great meeting you Harry! Looking forward to seeing you again. Please send me something re your company. Best Boris From: J <[email protected]> Sent: Thursday, November 1, 2018 3:15 PM To: Boris Nikolic Harry Fisch < > Subject: harry boris, boris harry please note The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to jeevacation@gmail com and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved EFTA01017712